PATIENT GROUP CONDEMNS NICE REVISED HEAVY MENSTRUAL BLEEDING GUIDELINES UNSAFE FOR WOMEN MANY MORE WOMEN WILL DIE AND SUFFER SERIOUS COMPLICATIONS

Similar documents
Heavy Menstrual Bleeding. Mr Nick Nicholas MD FRCOG Grad Dip Law. Consultant Gynaecologist

PATIENT CHOICE AND NICE COMPLIANCE SURVEY ON FIBROID TREATMENT ACUTE NHS TRUSTS IN ENGLAND CONDUCTED IN 2016

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health and social care directorate. Quality standards and indicators.

Menstrual Disorders & Ambulatory Gynaecology

Investigating HMB- an evidence based approach

Abnormal uterine bleeding:

Fibroid mapping. Haitham Hamoda MD FRCOG Consultant Gynaecologist, Subspecialist in Reproductive Medicine & Surgery King s College Hospital

Heavy menstrual bleeding (update)

Heavy menstrual bleeding: assessment and management

NICE guideline Published: 14 March 2018 nice.org.uk/guidance/ng88

Uterine artery embolisation for treating adenomyosis

HEAVY MENSTRUAL BLEEDING GUIDELINE CONSULTATION ON DRAFT SCOPE 20 Sept 15 Oct Commentator Section Comment Response WCH

Excessive menstrual blood loss

Not all roads point to hysterectomy: treatment options for fibroids

Hysteroscopy Clinic. Patient Information. Women and Children - Gynaecology

Center for Menstrual Disorders, Fibroids and Hysteroscopic Services

Hysterectomy. What is a hysterectomy? Why is hysterectomy done? Are there alternatives to hysterectomy?

Medical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health

Policy for Hysteroscopy Page 1 of 5. Policy for Hysteroscopy. V1.1 OPCS/ICD codes added. Version of: Version of: March 2018

Uterine sarcoma. Information for patients Gynaecology

Gynaecological cancers. Mr Vivek Nama MD MRCOG Consultant Gynaecological Oncologist

Endometrial Ablation for Heavy Menstrual Bleeding. Jonathan Lord Consultant gynaecologist

CLINICAL PRESENTATION AND RADIOLOGY QUIZ QUESTION

Hysteroscopy. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax

INTERVENTIONAL PROCEDURES PROGRAMME

An Update on the Management of Heavy Menstrual Bleeding

Minimal Access Surgery in Gynaecology

Facing Gynecologic Surgery?

Freedom of Information

Laparoscopy and Hysteroscopy

Your visit to the Outpatient Hysteroscopy Clinic

Treatment of Heavy Menstrual Bleeding: Ludkin (Nurse Hysteroscopist, Bradford Royal Infirmary) & M Rogers (Advanced

Fibroid Tumors And Endometriosis By Susan M. Lark READ ONLINE

Patient Input CADTH COMMON DRUG REVIEW. ulipristal acetate (Fibristal) (Allergan Inc.) Indication: Uterine fibroids (signs and symptoms)

Realizing dreams booklet.indd 1 5/20/ :26:52 AM

Healthcare Education Research

Dr John Short. Obstetrician and Gynaecologist Christchurch Women s Hospital Oxford Women's Health Christchurch

The 6 th Scientific Meeting of the Asia Pacific Menopause Federation

If you have any further questions, please speak to a doctor or nurse caring for you.

Pelvic Pain. What you need to know. 139 Dumaresq Street Campbelltown Phone Fax

National Heavy Menstrual Bleeding Audit

COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006

Outpatient Hysteroscopy. Patient Information

Gynaecology Cancer Red Flags. Dr Dina Bisson Consultant Obstetrician and Gynaecologist Southmead Hospital North Bristol NHS Trust 27 April 2017

PRE-ASS ESSMENT. Endometrial Ablation for Menorrhagia

Fibroids: diagnosis and management

Hysteroscopy. Department of Gynaecology. Patient information

The Centre for Reproductive Medicine HYSTERECTOMY

1 - Advanced clinical course for ART with Hands on

Shift your surgical ambition to surgical action

Health Board/Region: All-Wales

INTERVENTIONAL PROCEDURES PROGRAMME

NHS Forth Valley. Hysteroscopy. Patient Information Leaflet Department of Obstetrics and Gynaecology

Program Schedule. Update in Gynecology and Minimally Invasive Surgery 2018

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

Pedram Bral, M.D. Maimonides Medical Center Brooklyn, New York

Program Schedule. Update in Gynecology and Minimally Invasive Surgery 2018

Membership of Heavy Menstrual Bleeding (update) guideline Committee

Program Schedule. 3 rd Annual Collaborative Symposium: Update in Minimally Invasive Gynecologic Surgery

Laparoscopy-Hysteroscopy

Hysterectomy Fact versus fiction. Richard Dover Specialist Gynaecologist

Bursting Pelvic Inflammatory Disease.

Index. Note: Page numbers of article titles are in boldface type.

Fibroids. Very Common! Benign smooth muscle tumors of the myometrium 20-80% of women develop fibroids by age 50* 151 million women affected**

Laparoscopic laser myomectomy

Possible weight loss after fibroid removal

is hysterectomy right for you?

Endometriosis Information Leaflet

Core Module 7: Surgical Procedures

National Heavy Menstrual Bleeding Audit

One of the commonest gynecological cancers,especially in white Americans.

UTERINE LEIOMYOSARCOMA. About Uterine leiomyosarcoma

SURGICAL PROBLEMS IN FERTILITY- FIBROIDS. Dr.Māris Arājs gyn-ob specialist Cell phone:

MORE THAN FERTILITY SAFEGUARDING YOUR REPRODUCTIVE HEALTH WITH THE BILLINGS OVULATION METHOD

INTERVENTIONAL PROCEDURES PROGRAMME

Dr Mary Birdsall. Fertility Associates Auckland

CLEAR COVERAGE HYSTERECTOMY CHECKLISTS

Management of Uterine Myomas

Cervical Cancer - Suspected

WOMEN S HEALTH SERVICES

Comparative Study Between Robotic Laparoscopic Myomectomy and Abdominal Myomectomy

Current approaches to managing heavy menstrual bleeding

Introduction to GYN Specialties

The facts about Endometriosis

Evaluation of the Infertile Couple

Fertility Assessment and Treatment Pathway

POSTGRADUATE TRAINING AND ASSESSMENT IN OBSTETRICS AND GYNAECOLOGY LOG BOOK

GP Guidelines for the Management of Adult Patients with Gynaecological Cancers 2012

An MRI pictorial review of uterine fibroid expulsion after uterine artery embolisation

Cynthia Morris DO, FACOOG, FACOS Medical Director, Women s Wellness Center Fayette County Memorial Hospital

NHS. Laparoscopic helium plasma coagulation for the treatment of endometriosis. National Institute for Health and Clinical Excellence

Pathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer

Vaginal hysterectomy. Brought to you in association with EIDO Healthcare and endorsed by the Royal College of Surgeons England.

Familial Cancer Clinic Information Sheet. Surgery to prevent endometrial and ovarian cancer. in women with Lynch Syndrome

Female Genital Tract Lab. Dr. Nisreen Abu Shahin Assistant Professor of Pathology University of Jordan


5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist

Dr Devashana Gupta. Repromed Auckland. 17:30-18:00 Fibroids, Endometriosis and DUB

Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids

Gynaecological Oncology Cases

Transcription:

PRESS RELEASE For immediate release 20 th February 2018 PATIENT GROUP CONDEMNS NICE REVISED HEAVY MENSTRUAL BLEEDING GUIDELINES UNSAFE FOR WOMEN MANY MORE WOMEN WILL DIE AND SUFFER SERIOUS COMPLICATIONS The revised NICE Clinical Guidelines on Heavy Menstrual Bleeding [HMB], (which includes fibroids) launched today is unsafe for women. Many more women will die or suffer serious complications as a result of the changes. Informed choice for women will be reduced, safeguards for women have been removed and access to safer less invasive treatments made more difficult. These guidelines promote the interests of gynaecologists at the expense of safety for women. Hysteroscopy is recommended as a first line hospital diagnosis for heavy menstrual bleeding instead of ultrasound. Currently 180 women a year die in the NHS in England from hysteroscopy i and a further 3,000 ii women suffer serious complications. If hysteroscopy is to be used as a first line hospital diagnosis these deaths and serious complications could double or triple to over 500 deaths and over 8,000 serious complications each year. iii It is also excruciatingly painful for some women. iv Hysterectomy can now be used as a first-line treatment. The previous version of the NICE Guidelines stated Hysterectomy should not be used as a first line treatment solely for HMB. It also advocated the least invasive approach e.g. vaginal rather than abdominal. The new version does not do this. Over 180 women die in the NHS in England from hysterectomy each year and over 170,000 suffer serious complications. These figures will rise significantly with the rise in hysterectomies. v Healthy ovaries can now be removed. In the previous version of the NICE Guidelines it stated that Removal of healthy ovaries at the time of hysterectomy should not be undertaken. This has been removed so many more women will be persuaded to have oophorectomy to save them from cancer and suffer many side effects including instant menopause. vi Gynaecologists have no training or education in the safer less invasive treatments for fibroids uterine artery/fibroid embolisation [UAE/UFE] performed by Interventional Radiologists vii and these Guidelines have not recommended multi-disciplinary fibroid clinics where gynaecologists and

interventional radiologists work together so women can be fully informed about all treatments and many will only be offered hysterectomy. viii Recommendations have also been removed that women should be sent information on all possible treatment before their outpatient appointment. The new Guidelines recommend endometrial ablation should be used to treat fibroids >3cm, when this has only been formally assessed for safety and efficacy for small fibroids <3cm. Magnetic resonance guided ultrasound [MRgFUS], a non-invasive interventional radiology treatment has been positively assessed by NICE for safety and efficacy, but has been completely left out, so women will have great difficulty accessing it. Ginette Camps-Walsh the co-ordinator of FEmISA said The previous NICE Guidelines on HMB [2007] made significant advances in giving women access to safer, less invasive treatments that enabled women to retain their fertility with alternatives to hysterectomy as a first line treatment for heavy menstrual bleeding and fibroids >3cm. The new recommendations are not patient centred, promote old, less safe, very invasive procedures, particularly hysterectomy, which have never been reviewed for safety or efficacy, have a higher complication and death rate and are more expensive to the women, their families, their employers and the NHS. This is a very regressive step for women and the NHS and we condemn it. FEmISA estimates that the increased costs to the NHS, women and their families is unsustainable an additional 60 million p.a. for increased hysteroscopy alone. These recommendations are not cost effective for the NHS and particularly not for women. ix On the other hand, 61 million p.a. could be saved if 60% of the hysterectomies for fibroids were replaced by UAE and a further 76 million savings from earlier return to work after UFE compared with hysterectomy. x ENDS --ooooo-- For further information, please contact Ginette Camps-Walsh - at FEmISA 01865 351762, Mobile 07768 794061 or info@femisa.org.uk Web site www.femisa.org.uk INFORMATION FOR EDITORS Incidence Uterine fibroids or leiomyomata are the commonest benign tumours in women of reproductive age. Up to 80% of women develop uterine fibroids with 25-30% developing symptoms that need treatment. The peak incidence occurs between 35 and 40 years old. 64,500 women in England are diagnosed each year with fibroids and structural abnormalities of the cervix and other parts of the reproductive tract. NICE CLINICAL GUIDELINES ON HEAVY MENSTRUAL BLEEDING There are 4 in-patient treatments for fibroids

Hysterectomy removal of the uterus/womb either with or without the cervix. This is the least safe, most expensive and most common treatment. The women becomes infertile and has early menopause. It has never been formally reviewed for safety and efficacy. Myomectomy removal of the fibroid alone either abdominal or by hysteroscopic approaches. It allows a woman to retain her fertility. This has never been formally reviewed for safety and efficacy and the mortality and serious morbidity rate is unknown. Uterine Artery/Fibroid Embolisation [UAE/UFE] is newer treatment performed by Interventional Radiologists since 1980s. It has been formally, positively reviewed by NICE for safety and efficacy, is minimally invasive and has a very mortality rate no reported deaths at all in recent years. A woman retains her fertility. The hospital stay is overnight and the return to work much sooner than hysterectomy or myomectomy. Magnetic Resonance guided Focused Ultrasound [MRgFUS] - This is an Interventional Radiology minimally invasive treatment reviewed positively by NICE for safety and efficacy. For more information see the FEmISA web site - http://www.femisa.org.uk/index.php/about-fibroids Old NICE Clinical Guidelines on Heavy Menstrual Bleeding 2007 - https://www.nice.org.uk/guidance/cg44 Revised NICE Guidelines on HMB - https://www.nice.org.uk/guidance/indevelopment/gidng10012 These links may be changed by NICE.. REFERENCES i NHS HES ONS hospital mortality data ii The incidence of fluid overload - 1.6% and 2.5% (Agostini A 2002a; Overton 1997), uterine perforation is 0.014%, and infectious complications account for 0.3% to 1.6% of cases (Bradley 2002) average 3.4% iii Hysteroscopy No. Procedures p.a. @ 90 days No. Serious Complications - rate 3.4% Current Diagnostic 55,377 148 0.3% 1,883 Therapeutic 31,573 32 0.1% 1,073 Total 86,950 180 2,956 Projected x 2 Diagnostic 110,754 296 0.3% 3,766 Therapeutic 63,146 64 0.1% 2,147 Total 173,900 360 5,913 Projected x 3 Diagnostic 166,131 444 0.3% 5,648 Therapeutic 94,719 128 0.1% 3,220 Total 260,850 572 8,869

iv Increased mortality and morbidity from hysterectomy as first line treatment for HMB Hysterectomy No. Procedures p.a. @ 90 days No. Serious Complications - Serious Complication Maresh * Current Abdominal 31,086 176 0.6% 111,910 4.6% Vaginal 7,236 6 0.10% 26,050 7.10% Projected +20% Abdominal 37,303 211 0.6% 134,292 4.6% Vaginal 8,683 7 0.10% 31,260 7.10% Projected +30% Abdominal 40,412 229 0.6% 145,482 4.6% Vaginal 9,407 8 0.10% 33,864 7.10% *Maresh et AL The VALUE national hysterectomy study: description of the patients and their surgery 202 iv Pain for women from Hysteroscopy Hysteroscopy as a first line diagnosis for fibroids and endometriosis is unacceptable. It is very painful for many and not appropriate as an outpatient treatment. It has been described by Lyn Brown MP (West Ham) (Lab): in a parliamentary debate in 2013 from their women constituents experiencing it as absolute agony and Ms Brown went on to say This procedure, without anaesthesia, is barbaric. It is absolute torture. It needs to be stopped. At the very least, the patient should be informed that it could be extremely painful and have options explained and open for her. That way, she can make an informed decision as to whether to go ahead without anaesthesia. Another patient was given a hysteroscopy under local anaesthetic and commented - the procedure was still very uncomfortable and painful. I have to say that I think offering a hysteroscopy without any form of anaesthetic is barbaric. Another woman asked about the pain said it was excruciating. There are many more such quotes directly from women who have experienced hysteroscopy. Bob Stewart MP : May I ask what percentage of women feel no pain whatsoever? There was no answer at the time, it is probably none there are no women who do not suffer pain. vi The incidence of ovarian cancer is 2% (Cancer Research UK) vii FEmISA Report - Patient Choice and Nice Compliance for Fibroid Treatment - http://www.femisa.org.uk/images/femisa%20report%20on%20patient%20choice%20and%20nice%20c ompliance%209.17%20-%20final.pdf viii Women s Health APPG Report - https://static1.squarespace.com/static/5757c9a92eeb8124fc5b9077/t/58d8ca34f7e0ab027a19247c/1490 602579808/APPG+Womens+Health+March+2017+web+title.pdf

ix Cost Hysteroscopy is not cost Effective The NHS Tariff for an abdominal ultrasound is 40 for hysteroscopy is 340. This excruciatingly painful and barbaric procedure as well as being very expensive to women also costs the NHS and taxpayer is 850% more expensive. There are currently 55,377 diagnostic hysteroscopy procedures and 31,573 therapeutic ones pa. with a total cost of 29.5million. If all women with suspected structural abnormalities were given hysteroscopy instead of ultrasound this figure is likely to double or triple as per model in comment 3. 64,500 women are diagnosed each year with fibroids and structural abnormalities of the cervix and other parts of the reproductive tract. It would also be expensive for women, their families and employers, as ultrasound is a quick non-invasive procedure taking a few minutes, while hysteroscopy even in outpatients is likely to require a whole day off work and require a family member too escort them. x See Cost comparison on the FEmiSA web site - http://www.femisa.org.uk/index.php/costcomparisons